Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163432 · ClinicalTrials.gov registry record · Phase 2
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
A Phase 2 study of Non Small Cell Lung Cancer Metastatic, sponsored by University of Utah.
- Active
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT04163432: Active Phase 2 study of Non Small Cell Lung Cancer Metastatic, sponsored by University of Utah.
NCT04163432 is a Phase 2 study of Non Small Cell Lung Cancer Metastatic that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 43 participants, below the 434-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04163432, a Phase 2 study of Non Small Cell Lung Cancer Metastatic, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.
Primary Outcome
Clinical Benefit is the count of participants who have achieved a CR (Complete Response), PR (Partial Response), or SD (Stable Disease), assessed by RECIST 1.1 response criteria Response Evaluation Criteria in Solid Tumors (RECIST) is a standard measure of how well cancer patients respond to treatment. Possible scores are CR (total disappearance of all target lesions), PR (at least a 30% decrease of the sum of the longest diameter of all target lesions), PD (Progressive Disease; at least a 20%
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Durvalumab
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT04163432 still lists
NCT04163432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 434-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT04163432 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04163432 about?
NCT04163432 is a clinical study titled "Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC". This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.
What is the current status of trial NCT04163432?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2020-06-16. Estimated completion is 2026-12.
What conditions does trial NCT04163432 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic.
What interventions are being tested in trial NCT04163432?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04163432?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04163432 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Small Cell Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04163432's enrollment target sits among peer trials
43 16th of 16 higher than 1 of 16 other Non Small Cell Lung Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non Small Cell Lung Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
ACTIVE NOT RECRUITING · Phase 2
-
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI